Insights from 2023 ESMO Annual Meeting


 

ESMO 2023 Insights: "DESTINY-Breast04 Study Updated Survival Results - T-DXd vs. Treatment of Physician’s Choice in Patients With HER2-Low Unresectable and/or Metastatic Breast Cancer"

331 views
November 3, 2023
Comments 0
Login to view comments. Click here to Login